Pharmaceutical Grade Lactose Offers Efficient Compatibility with Active Ingredients

4 June 2020: The pharmaceutical grade lactose market is witnessing considerable growth due to increase in infant population across the regions. It also has quality characteristics such as immune cell activation and iron absorption, and produces cytokines, driving the growth of the market in the coming years. 

Pharmaceutical grade lactose is used while manufacturing capsules and pharmaceutical tablets as fillers. Number of support initiatives from government bodies and rising awareness about usage of pharmaceutical grade lactose are the factors promoting growth of the market. It is also used as drug formulation, in nanotechnology, and also an excipient in drugs as it is efficiently compatible with other active ingredients. 

Support from the Various Government Bodies Promote Market Growth

On the basis of region, Europe held the largest market share due to the presence of a well-established healthcare sector and outsourcing of pharmaceutical products. Factors likely to propel growth of the market are product development and innovation due to different initiatives undertaken by regional governments.

Increasing demand for infant formula is expected to fuel the industry growth in North America. Government policies motivating and supporting the regional players to increase investment is anticipated to encourage growth of the pharmaceutical grade lactose in the coming years.

In developing countries such as India and China, increasing birth rate has resulted in high demand for the pharmaceutical grade lactose. Low labor costs and lack of stringent government regulations are factors responsible for increased production. Efforts to provide affordable medicines by governments and prevalence of chronic diseases are anticipated to drive the market in Central and South America over the forecast period. 

Market Insights

Leading Companies are keen to expand their portfolio by employing various strategies such as collaborations, joint ventures, new product development, partnerships, and agreements in order to strengthen their market presence. Major players are inclined to focus on new strategies and are investing in R&D to gain a competitive edge in the market. 

Leading market players of the pharmaceutical grade lactose market include Kerry Inc.; Merck KGaA; BASF SE; ALPAVIT; BASF SE; Meggle; Armor Pharma; Novartis AG; Sigma-Aldrich Corporation; GlaxoSmithKline plc; Bayer AG, Abbott Laboratories; AstraZeneca plc; and DFE Pharma.

Nanoparticles Improve the Efficacy of Medicines

Prevalence of cancer and other chronic diseases has boosted research activities in healthcare sector. Researchers are keen on discovering treatments that can cure diseases at cellular level. Nanoparticles can safely transport drugs to the designated location without being affected by temperatures within the body.

Metal & Metal Oxide Nanoparticles

Nanoparticles (NP) are the minute molecules between the ranges of 100 to 2500 nanometers. They gained prominence in the healthcare sector due to their use in targeted therapies. Nanoparticles are used in customized treatments for direct elimination of cancerous cells. Success of these molecules has encouraged research activities to improve the efficacy of drugs.

Metal oxide NPs have anti-corrosive and anti-bacterial properties. Hence, there is a high demand for them from the healthcare sector. They are also known as nanopowders or nanocrystals. Government-backed initiatives like the National Nanotechnology Initiative (NNI) support research & development activities. Rising drug-resistant diseases and various cancers are buttressing the need of these molecules.

Immune Modifying Nanoparticles

Cour Pharmaceutical Development Company, a US-based corporation, has published a study regarding the efficacy of its nanoparticle therapy. According to this study, animals injected with Immune Modifying Nanoparticles (IMP) showcased a reduction in the size of heart lesions. Further studies can determine potential benefits of IMP for humans.

NPs for Dental Health and Cancer Treatment

Researchers at the University of Pennsylvania’s School of Dental Medicine and University of Rochester have observed the potential of NPs in fighting tooth decay and plaque. Farnesol, an antibacterial agent can be encased in nanocages to target dental plaque. Similarly, researchers at the University of Missouri are attempting to prove the efficiency of gold NPs in treating prostate cancer in dogs. The resulting success of this study can be then tested on humans.

Market Overview

The worldwide nanoparticles - metal & metal oxides in healthcare market can reach USD 81 billion by 2025, according to Grand View Research, Inc. It is projected to register a significant CAGR over the forecast period (2014 to 2025). High approval rate and versatile applications can propel the growth in the near future.

In 2016, gold nanoparticles dominated the overall market on account of revenue due to its applications in human therapeutics. Better compatibility and low toxicity of gold NPs can further boost their demand in the forthcoming years. In-vivo imaging emerged as the largest application in 2016. Use of Au3Cu1 nanoshells in magnetic resonance (MR) angiography is the key driving factor. Notable market players are AstraZeneca, Immunolight LLC, Merck KGaA, and nanoComposix.

Read more at:
http://www.grandviewresearch.com/industry-analysis/nanoparticles-metal-oxides-in-healthcare-market

Novel Hepatitis Therapeutics for Revolutionary Treatment

Hepatitis is the inflammation of liver cells. It is caused due to excessive alcohol consumption, viral infection, autoimmune diseases, medication errors, nonalcoholic steatohepatitis, and toxins. Acute and chronic are the two basic categories of hepatitis. Acute hepatitis lasts for less than six months. If the condition persists even after six months then it is considered as chronic hepatitis. People with HCV-infected sexual partners, HIV infections, intranasal & injectable drug users, and recipients of infected blood products are at a high risk of hepatitis. Unhygienic conditions can also transmit this disease at a rapid pace.

HBV Infection & Its Causes

Hepatitis B Virus (HBV) infections can lead to several other liver diseases such as acute self-limited hepatitis, subclinical infection, and Chronic Hepatitis B (CHB) caused by continual infection. CHB can lead to liver cirrhosis and liver cancer. Both of these potentially lethal diseases are considered as some of the leading causes of deaths on the global scale.

A Revolutionary Cure for Hepatitis B

A new therapeutic vaccine “ABX2013” is said to transform the regular CHB treatment. This disease affects majority of global population and results in almost over a million deaths every year. This vaccine has reportedly shown considerably fewer adverse effects than other existing immunotherapeutic approaches. It is much easier to administer. This drug can control viral load for a longer time period. Viral load is the amount of hepatitis virus present in the blood of a person suffering from hepatitis.

Market Insights

According to a report by Grand View Research, Inc.; the global hepatitis therapeutics market is expected to witness high growth over the forecast period (2014 to 2025). Increasing number of various autoimmune diseases, high incidence of viral hepatitis, and rising healthcare expenditures and geriatric population can drive the global market in the years to come. Johnson & Johnson; Merck & Co., Inc.; AbbVie Inc.; and Bristol-Myers Squibb Company are some of the key companies operating in the worldwide market for hepatitis therapeutics.

In-Depth Research Report On Hepatitis Therapeutics Market:
http://www.grandviewresearch.com/industry-analysis/hepatitis-therapeutics-market